Search research articles
Contact Us
Filters
Showing results (491-500 of 505) with videos related to
Page
of 51
Sort By:
Molecular Psychiatry
|
March 7, 2007
More evidence supports the association of PPP3CC with schizophrenia
Y L Liu, C S J Fann, C M Liu, et al.
Plos One
|
April 22, 2020
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C C Liu, Holly Koblish, Liangxing Wu, et al.
Journal of Medicinal Chemistry
|
June 23, 2006
Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic
Andrew P Combs, Wenyu Zhu, Matthew L Crawley, et al.
Science Translational Medicine
|
March 13, 2020
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
Johanna M Schafer, Brian D Lehmann, Paula I Gonzalez-Ericsson, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
August 26, 2020
[Population's acceptance and attitude toward a novel fecal immunochemical test for colorectal cancer screening: a multi-center survey in China]
H Wang, C C Liu, F Z Bai, et al.
Cancer Biology & Therapy
|
April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells
Phillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
Matthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 30, 2020
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
Niu Shin, Matthew Stubbs, Holly Koblish, et al.
Cancer Discovery
|
March 7, 2022
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Holly K Koblish, Liangxing Wu, Liang-Chuan S Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
January 10, 2020
[Analysis on the health literacy of the cancer prevention and treatment and its related factors among urban residents in China from 2015 to 2017]
P Dong, J F Shi, W Q Qiu, et al.
Page
of 51
Search research articles
Search
Showing results (491-500 of 505) with videos related to
Sort By:
Page
of 51
Molecular Psychiatry
|
March 7, 2007
More evidence supports the association of PPP3CC with schizophrenia
Y L Liu, C S J Fann, C M Liu, et al.
Plos One
|
April 22, 2020
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C C Liu, Holly Koblish, Liangxing Wu, et al.
Journal of Medicinal Chemistry
|
June 23, 2006
Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic
Andrew P Combs, Wenyu Zhu, Matthew L Crawley, et al.
Science Translational Medicine
|
March 13, 2020
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
Johanna M Schafer, Brian D Lehmann, Paula I Gonzalez-Ericsson, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
August 26, 2020
[Population's acceptance and attitude toward a novel fecal immunochemical test for colorectal cancer screening: a multi-center survey in China]
H Wang, C C Liu, F Z Bai, et al.
Cancer Biology & Therapy
|
April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells
Phillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
Matthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 30, 2020
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
Niu Shin, Matthew Stubbs, Holly Koblish, et al.
Cancer Discovery
|
March 7, 2022
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Holly K Koblish, Liangxing Wu, Liang-Chuan S Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
January 10, 2020
[Analysis on the health literacy of the cancer prevention and treatment and its related factors among urban residents in China from 2015 to 2017]
P Dong, J F Shi, W Q Qiu, et al.
Page
of 51